EUVIMEDEUVIMED entdecken
Multizentrische Studie

Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma

Derk C F Klatte iD, Jason S Starr iD, Kristin E Clift iD, Heather D Hardway, Jeanin E van Hooft iD, Monique E van Leerdam iD, Thomas P Potjer, R John Presutti iD, Douglas L Riegert-Johnson, Michael B Wallace, Yan Bi iD

JCO Oncology Practice · 2024

DOI: 10.1200/op.23.00447 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Oncology Practice, 2024. Verfasst von Derk C F Klatte und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Genetic Testing, Pancreatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Guidelines recommend germline genetic testing (GT) for patients with pancreatic ductal adenocarcinoma (PDAC). This study aims to evaluate the utilization and outcomes of multigene panel GT in patients with PDAC. METHODS This retrospective, multisite study included patients with PDAC diagnosed between May 2018 and August 2020 at Mayo Clinic Arizona, Florida, and Minnesota. Discussion, uptake, and outcomes of GT were compared before (May 1, 2018-May 1, 2019) and after (August 1, 2019-August 1, 2020) the guideline update, accounting for a transition period. RESULTS The study identified 533 patients with PDAC, with 321 (60.2%) preguideline and 212 (39.8%) postguideline. Patient characteristics did not differ between the preguideline and postguideline periods. GT was discussed in 34.3% (110 of 321) of preguideline and 39.6% (84 of 212) of postguideline patients (odds ratio [OR], 1.26 [95% CI, 0.88 to 1.80]) and subsequently performed in 80.9% (89 of 110) of preguideline and 75.0% (63 of 84) of postguideline patients (OR, 1.10 [95% CI, 0.75 to 1.61]). Of 152 tested patients, 26 (17.1%) had a pathogenic variant (PV), of whom 17 (11.2%; 17 of 152) were PDAC-associated. Over the entire study period, GT was more likely in younger patients (65 v 70 years; P < .001), those seen by a medical oncologist (82.9% v 69.0%; P < .001), and those surviving more than 12 months from diagnosis (70.4% v 43.4%; P < .001). Demographics and personal/family cancer history were comparable between patients with and without a PDAC PV. CONCLUSION GT remains underutilized despite National Comprehensive Cancer Network guideline recommendations. Given the poor prognosis of PDAC and potential implications of GT, efforts to increase utilization are needed to provide surveillance and support to both patients with PDAC and at-risk family members.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalGenetic TestingPancreatic NeoplasmsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAged, 80 and overAdult

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL.
  • Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL.
  • Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL.
  • Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.

ORCID-Profile: Derk C F Klatte, Jason S Starr, Kristin E Clift, Jeanin E van Hooft, Monique E van Leerdam, R John Presutti, Yan Bi

Zitieren

APA

Klatte, D. C. F., Starr, J. S., Clift, K. E., Hardway, H. D., van Hooft, J. E., van Leerdam, M. E., Potjer, T. P., Presutti, R. J., Riegert-Johnson, D. L., Wallace, M. B., & Bi, Y. (2024). Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma. JCO Oncology Practice. https://doi.org/10.1200/op.23.00447

Vancouver

Klatte DCF, Starr JS, Clift KE, Hardway HD, van Hooft JE, van Leerdam ME, et al. Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma. JCO Oncology Practice. 2024. doi:10.1200/op.23.00447

BibTeX
@article{Klatte2024,
  author = {Klatte, Derk C F and Starr, Jason S and Clift, Kristin E and Hardway, Heather D and van Hooft, Jeanin E and van Leerdam, Monique E and Potjer, Thomas P and Presutti, R John and Riegert-Johnson, Douglas L and Wallace, Michael B and Bi, Yan},
  title = {Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma},
  journal = {JCO Oncology Practice},
  year = {2024},
  doi = {10.1200/op.23.00447}
}
Kostenlos starten →